Ascentage Pharma Group International 6855
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Ascentage Pharma Group International? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
HKEX
Type
Biotech
Sector
Biotechnology, oncology therapeutics
We're already tracking Ascentage Pharma Group International — here are the latest events we've registered
Recent News
- In June 2026, Ascentage Pharma presented updated clinical data for its lead candidate olverembatinib at the ASCO Annual Meeting. The data demonstrated sustained therapeutic efficacy and a manageable safety profile in patients with resistant chronic myeloid leukemia.
What Firelda Watch includes for Ascentage Pharma Group International
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Ascentage Pharma Group International will be delivered in the same format.
Want to follow Ascentage Pharma Group International? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.